Revenue: As of FY2026 Q1, the actual value is USD 403.48 M, beating the estimate of USD 386.12 M.EPS: As of FY2026 Q1, the actual value is USD 0.04, beating the estimate of USD 0.0081.EBIT: As of FY2026 Q1, the actual value is USD 24.08 M.<h4>Revenue</h4>LifeStance Health Group, Inc. reported Q1 2026 revenue of $403.5 million, marking a 21% increase year-over-year compared to $333.0 million in Q1 2025 . Total Revenue Per Visit (TRPV) was $163.5 in Q1 2026, up from $158.7 in Q1 2025 .<h4>Operational Metrics</h4>Net Income: Net income for Q1 2026 was $14.2 million, significantly up from $0.7 million in Q1 2025 .Income from Operations: Income from operations for Q1 2026 was $22.3 million, compared to $1.6 million in Q1 2025 .Operating Costs: Center costs, excluding depreciation and amortization, were $267.5 million in Q1 2026, compared to $223.2 million in Q1 2025 . General and administrative expenses were $100.3 million in Q1 2026, compared to $94.4 million in Q1 2025 . Depreciation and amortization was $13.3 million in Q1 2026, down from $13.8 million in Q1 2025 .Center Margin (Non-GAAP): Center Margin for Q1 2026 was $135.9 million, or 33.7% as a percentage of revenue, compared to $109.8 million, or 33.0% in Q1 2025 .Adjusted EBITDA (Non-GAAP): Adjusted EBITDA for Q1 2026 was $51.1 million, or 12.7% as a percentage of revenue, compared to $34.6 million, or 10.4% in Q1 2025 .<h4>Cash Flow</h4>Operating Cash Flow: Net cash provided by operating activities was $33.1 million in Q1 2026, a substantial improvement from net cash used in operating activities of -$3.1 million in Q1 2025 .Free Cash Flow: Free Cash Flow was $22.3 million in Q1 2026, compared to -$10.3 million in Q1 2025 .Investing and Financing Activities: Net cash used in investing activities was -$13.9 million in Q1 2026, while net cash used in financing activities was -$73.0 million .Cash and Cash Equivalents: The company ended Q1 2026 with cash and cash equivalents of $194.8 million .<h4>Unique Metrics and Capital Allocation</h4>Clinicians: The total number of clinicians reached 8,349, an 11% increase year-over-year, with 309 net clinician additions in Q1 2026 .Visit Volumes: Q1 2026 visit volumes increased by 18% year-over-year to 2.5 million .Capital Expenditures: Capital expenditures for Q1 2026 were $11 million .Debt: Net long-term debt was $263 million at the end of Q1 2026 .Strategic Investments: LifeStance Health Group, Inc. opened 6 new centers and completed 2 tuck-in acquisitions during Q1 2026 . The company also repurchased $49.1 million of common stock .<h4>Outlook / Guidance</h4>For the full year 2026, LifeStance Health Group, Inc. raised its revenue guidance to $1,640 – $1,680 million, Center Margin to $547 – $571 million, and Adjusted EBITDA to $200 – $220 million . For Q2 2026, the company expects revenue between $405 – $425 million, Center Margin between $135 – $147 million, and Adjusted EBITDA between $50 – $60 million . These projections assume 20 to 30 new center openings for the full year .

LifeStance Health | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 403.48 M